Immunotherapy for
Breast Cancer

Immunotherapy for breast cancer is a new way to help the body’s immune system fight breast cancer cells better. Unlike traditional treatments like chemotherapy, which directly attack cancer cells, immunotherapy helps the body’s natural defenses work harder to fight cancer. Cancer immunotherapy has gained attention as an effective treatment option, particularly for harder-to-treat cancers like triple-negative breast cancer.

Hope for Harder-to-Treat Cancers

It has been especially helpful in treating types of breast cancer that are harder to treat, like triple-negative breast cancer. In this article, we will explain how immunotherapy works for breast cancer, its benefits, the types of treatments available, side effects, and why it might be the right choice for you.

The Food and Drug Administration (FDA) has approved several immunotherapy drugs, which have shown positive results in treating certain types of breast cancer. These FDA-approved immunotherapy drugs help boost the body’s immune response, making it easier to target and fight cancer cells effectively.

How Does Immunotherapy for Breast Cancer Work?

Immunotherapy boosts the body’s immune system to help it find and destroy breast cancer cells. Cancer cells often hide from the immune system by turning off its ability to fight. Immunotherapy helps by targeting special proteins or other ways that cancer cells avoid being attacked. The goal is to make the immune system better at spotting and fighting cancer.

For example, immune checkpoint inhibitors block signals that stop immune cells from attacking cancer cells. By stopping these signals, these drugs allow immune cells to attack cancer more freely, improving the immune system’s ability to fight the disease.

Training the Immune System to Recognize Cancer

One of the key strengths of immunotherapy is its ability to train the immune system to detect cancer cells more accurately. Over time, this “training” helps the body build a memory of cancer cell markers, making it easier to prevent recurrence and offering a longer-lasting defense compared to some traditional treatments.

Why Choose Immunotherapy for Breast Cancer?

There are several reasons why immunotherapy could be the right treatment for your breast cancer:

Works for Hard-to-Treat Cancers

Immunotherapy excels at treating more aggressive types of breast cancer, such as triple-negative and HER2-positive breast cancer. These cancers often resist chemotherapy but respond well to immunotherapy.

Fewer Side Effects

Compared to chemotherapy, immunotherapy usually causes fewer side effects. Since it helps the immune system target cancer cells, it doesn’t harm healthy cells as much, leading to a better quality of life during treatment.

Can Combine with Other Treatments

Doctors often use immunotherapy along with other treatments like chemotherapy and targeted therapy for better results. This combination can shrink tumors, slow down cancer growth, and improve survival rates.

Types of Immunotherapy for Breast Cancer

Several types of immunotherapy treatments help the immune system fight breast cancer. These treatments aim to help the body recognize and destroy cancer cells more effectively. Here are some common immunotherapy options for breast cancer:

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors help the immune system recognize breast cancer cells as harmful and attack them. These drugs block specific proteins on cancer cells that stop immune cells from doing their job. These drugs are especially effective when cancer cells have high levels of checkpoint proteins, which makes it easier for the immune system to target them.

Doctors often combine these inhibitors with chemotherapy for stronger results and better outcomes. FDA approval means these drugs are widely used to treat aggressive types of cancer, including triple-negative breast cancer.

Monoclonal Antibodies

Monoclonal antibodies are lab-made proteins that target specific molecules on breast cancer cells. These antibodies either help the immune system find and destroy the cancer cells or block the signals that let cancer cells grow. For example, a common monoclonal antibody targets the HER2 receptor in HER2-positive breast cancer, making the cancer cells easier for the immune system to attack. Doctors often use monoclonal antibodies with chemotherapy to improve their effectiveness.

These antibodies are especially helpful for cancers with high levels of HER2, which makes them more vulnerable to treatment. Since the FDA has approved them, they are now a standard treatment for HER2-positive breast cancer, improving survival rates for many patients.

Cancer Vaccines

Cancer vaccines teach the immune system to recognize and attack breast cancer cells. Vaccines like neuVax are meant to boost the immune response against cancer, especially in early-stage breast cancer.

While these vaccines are still being tested, they show promise in increasing the immune system’s ability to fight cancer and preventing the cancer from coming back. Cancer vaccines can work with chemotherapy to make the treatment stronger.

These vaccines aren’t widely used yet, but as research continues, they may become an important part of breast cancer treatment. The FDA is watching their progress in clinical trials, and they may soon be more commonly used. Early research shows that these vaccines can significantly improve the immune system’s ability to fight certain types of cancer.

Adoptive Cell Transfer (ACT)

Adoptive cell transfer (ACT) is a treatment where doctors take immune cells (usually T-cells) from the patient, change or improve them in a lab, and then put them back in the body.

These cells are trained to recognize and fight breast cancer cells more effectively. This treatment can help advanced breast cancer, especially when other treatments haven’t worked.

ACT is still being tested in clinical trials, but it might become an option for patients whose cancer has spread or become resistant to other treatments. When doctors combine ACT with chemotherapy, it can help boost the immune response and improve outcomes for patients with metastatic breast cancer.

The FDA is closely monitoring ACT as a possible treatment for advanced cancers.

Cytokine Therapy

Cytokine therapy uses special proteins called cytokines to boost the immune system and encourage immune cells to work better. Cytokines like interleukins and interferons stimulate the immune system to fight cancer. Though doctors do not commonly use cytokine therapy for breast cancer, they may consider it in some cases, especially when other treatments don’t work.

For some patients, cytokine therapy increases the number of immune cells available to attack cancer. Doctors can also use it with chemotherapy to increase the overall immune response, especially when cancer is more aggressive or advanced.

Although doctors do not use cytokine therapy as often as other treatments, researchers consider it an exciting area of study, and they may use it more in the future. The FDA could approve cytokine therapy for certain cancers, offering more treatment options for advanced breast cancer.

These immunotherapy treatments change how doctors treat breast cancer. By strengthening the immune system and targeting specific features of cancer cells, immunotherapy provides a more personalized approach to care. When doctors use it with chemotherapy, it shows great promise in treating even aggressive forms of breast cancer, such as triple-negative breast cancer. As research progresses, these treatments will likely play an even more important role in breast cancer care, offering new hope for patients with advanced or hard-to-treat cancers.

Treatment By Stage

Guiding Your Personalized Treatment Journey

Oligodendroglioma

Astrocytoma

Glioblastoma

Benefits of Immunotherapy for Breast Cancer

Immunotherapy offers several advantages over traditional treatments like chemotherapy:

Reduced Side Effects

First and foremost, immunotherapy causes fewer side effects than chemotherapy because it primarily targets cancer cells while sparing healthy cells.

Better for Certain Types of Breast Cancer

Additionally, this treatment proves effective for aggressive cancers like triple-negative and HER2-positive breast cancer, which often resist chemotherapy.

Potential for Long-Term Results

Furthermore, in many cases, immunotherapy controls breast cancer for extended periods. When combined with chemotherapy or targeted therapy, it significantly enhances the immune system’s ability to fight the disease even after treatment ends.

Your Journey

Start Your Recovery

Our dedicated Patient Navigator will assist you with appointment scheduling. Contact us at +6012-3993260 (Call or Whatsapp ).

First Consultation

On appointment day, bring along all the medical reports and your identity documents, ie. identity card or passport. Our team will help you organize the medical reports for our oncologist to review. Our oncologist will discuss the treatment plan with you. Tele-consult is available for overseas patients.

Treatment Day

Come to our center on an agreed date and time for the treatment. Our team will take good care of you. You will be discharged on the same day. Yes, you will get to go home after every treatment visit as no overnight admission is required.

Stay on Track

Our dedicated patient navigator will be following up with you post treatment to check on your condition, to ensure that you are doing well. You will receive a reminder message on your phone for the next appointment date.

Dr. Christina Ng Van Tze

Consultant Medical Oncologist
Medical Director
MBBS (Melb) FRACP (Aus)

Monday - Friday : 08:00 AM TO 06:00 PM

Saturday : 08:00 AM TO 02:00 PM

D. Joseph K. Joseph

Consultant Medical Oncologist
MBBCH, BAO (IRE) MRCP (UK)

Wednesday : 08:00 AM TO 12:00 PM

Friday : 08:00 AM TO 12:00 PM

Advocacy Programs

Dr. Christina Ng Represents Onco Life Centre at ESMO 2025

Hello, I’m Dr. Christina Ng Van Tze, a Consultant Medical Oncologist and Medical Director at Onco Life Centre, as well as the Founder President of Empowered The Cancer Advocacy Society of Malaysia. Throughout my career, I have been passionate about advancing personalized cancer treatment, strengthening community advocacy, and expanding access to high-quality care for patients across Malaysia.

Attending the ESMO Congress 2025 in Berlin was both inspiring and energizing. Representing Onco Life Centre, our dedicated medical centre in Malaysia, I stood among global leaders committed to shaping the future of oncology. This year’s congress was filled with remarkable scientific breakthroughs, thoughtful discussions, and a renewed sense of purpose as we work toward better outcomes and better lives for our patients.

A Global Gathering Focused on Precision Cancer Care

ESMO 2025 brought together thousands of clinicians, researchers, and advocates from around the world. What made this year particularly exciting was the strong emphasis on precision medicine, from cancer genetics and molecular profiling to advanced imaging and AI-powered diagnostic tools. These advancements are aligning closely with the work we do at Onco Life Centre, where patient individuality and tumor biology guide our treatment decisions.

Throughout the congress, many experts highlighted the importance of understanding each patient’s tumor in greater depth. Whether through genomic sequencing, circulating tumor DNA, or radiomic analyses, the oncology community is moving firmly toward personalized strategies. As someone who has long championed individualized care, I found these sessions especially meaningful.

Key Scientific Sessions That Inspired Me

One of the standout presentations was the evERA BC trial, a major study evaluating the combination of giredestrant, an oral SERD, with an mTOR inhibitor drug in hormone receptor-positive breast cancer. The results showed a significant improvement in progression-free survival, especially in tumors driven by ESR1 mutations. For patients who have progressed on CDK4/6 inhibitors, this combination may become an essential addition to our treatment toolbox.

This study also supports a larger movement within oncology—creating thoughtful, layered treatment plans that address resistance pathways and extend the time patients can remain on endocrine-based therapies. It’s a direction that can profoundly benefit Malaysian women, many of whom are diagnosed at younger ages or have aggressive tumor profiles.

Insights from the thoracic oncology sessions were equally impactful. Advances in lung cancer, including AI-driven pathology models, updated ALK-targeted treatment strategies, and ctDNA-guided therapy adjustments, reminded me just how quickly this field is evolving. Given the increasing prevalence of lung cancer in Malaysia, especially among non-smokers and women, these developments hold tremendous value for our community.

The Role of AI in Transforming Clinical Practice

One major theme across the congress was the integration of artificial intelligence into clinical decision-making. Researchers demonstrated how AI models can analyze pathology slides, radiology images, and genomic data to predict which patients are more likely to respond to immunotherapy or targeted treatment. These tools help us avoid ineffective therapies and guide patients toward options with the most tremendous potential.

At Onco Life Centre, we have been exploring the use of digital technologies to streamline assessments and enhance patient monitoring. Seeing the global oncology community embrace these tools assures me that we are moving in the right direction. I hope that AI will continue to improve early detection, refine treatment selection, and ultimately support better survival outcomes for Malaysian patients.

Representing Onco Life Centre on the International Stage

Representing Onco Life Centre at an event of this scale was a true honor. Our centre has always focused on delivering holistic, science-driven care, and it was wonderful to share our experiences with colleagues from around the world. I had meaningful conversations about challenges related to access to molecular testing globally, variability in treatment availability, and the need for stronger psycho-oncology support systems.

These interactions not only validated the work we do but also highlighted areas where we can continue to grow. Bringing international insights back to Malaysia ensures that our patients benefit from the same cutting-edge thinking shaping care in Europe, America, and beyond.

Bringing ESMO Insights Home to Malaysia

Returning from Berlin, I feel a renewed commitment to integrating the latest research into our daily practice. In the coming months, we aim to:

Enhance our use of molecular profiling for breast, lung, and gastrointestinal cancers
Expand ctDNA testing where appropriate to guide treatment decisions
Strengthen multidisciplinary discussions for complex cases
Continue investing in supportive care and psycho-oncology services
Provide patients and families with clearer, more personalized education about treatment choices

As a clinician, I believe that every advancement, no matter how technical, must ultimately translate into compassionate, human-centered care. This balance of science and empathy remains at the core of our mission.

A Future of Hope and Collaboration

ESMO 2025 reaffirmed what I’ve always believed: oncology is advancing rapidly, but meaningful progress relies on collaboration, continuous learning, and a deep commitment to patient care. I’m genuinely grateful for the opportunity to represent Onco Life Centre on this global platform. Being part of these critical conversations strengthens our mission to raise the standard of oncology in Malaysia. It ensures our patients benefit from the latest, most effective innovations in cancer care.

Moving forward, we will continue engaging with global partners, conducting meaningful advocacy through Empowered, and ensuring our patients receive the highest standard of personalized treatment.

Together, we can build a future where every individual facing cancer feels seen, supported, and empowered.

Onco Life Centre Wins 2025 Best Oncology Clinic in Malaysia

We are proud to share that Onco Life Centre has been named the Oncology Clinic and Treatment Centre of the Year in Malaysia at the GlobalHealth Asia-Pacific Awards 2025, held in Bangkok.

This prestigious recognition is a testament to our unwavering commitment to delivering personalized, compassionate, and cutting-edge cancer care to our patients. The award reflects not just our clinical excellence, but our dedication to safety, community outreach, and innovation in oncology services.

The GlobalHealth Asia-Pacific Awards celebrate leading healthcare institutions across the region. Winners are chosen based on a comprehensive evaluation of criteria such as:

Excellence and Innovation: Transforming healthcare delivery and patient outcomes through progressive medical practices.
Patient Safety: Upholding the highest standards to ensure safe, comfortable, and effective treatment environments.
Community Involvement: Actively engaging in public awareness, screening programs, and care for underprivileged communities.
Technology Adoption: Integrating advanced diagnostics, therapies, and digital tools to enhance every aspect of care.
Impact and Measurable Results: Demonstrating tangible improvements in cancer detection, treatment success, and patient well-being.
Adaptability and Preparedness: Being resilient and forward-thinking in the face of global health challenges.
Leadership and Vision: Cultivating a culture that prioritizes empathy, innovation, and ongoing education.

This award inspires us to continue raising the bar in oncology care—not only through medical advancements but by remaining deeply rooted in our advocacy mission: to serve, educate, and empower every cancer patient, especially those most in need.

We dedicate this achievement to our patients, survivors, caregivers, and the entire Onco Life Centre community. Your courage fuels our purpose. Together, we will continue the fight—because every life matters.